Flomoxef
Clinical data
Trade namesFlumarin
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
  • (6R,7R)-7-[[2-(Difluoromethylsulfanyl)acetyl]amino]-3-[[1-(2-hydroxyethyl)tetrazol-5-yl]sulfanylmethyl]-7-methoxy-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H18F2N6O7S2
Molar mass496.46 g·mol−1
3D model (JSmol)
Melting point82.5 to 87.5 °C (180.5 to 189.5 °F)
  • CO[C@@]1([C@@H]2N(C1=O)C(=C(CO2)CSc3nnnn3CCO)C(=O)O)NC(=O)CSC(F)F
  • InChI=1S/C15H18F2N6O7S2/c1-29-15(18-8(25)6-31-13(16)17)11(28)23-9(10(26)27)7(4-30-12(15)23)5-32-14-19-20-21-22(14)2-3-24/h12-13,24H,2-6H2,1H3,(H,18,25)(H,26,27)/t12-,15+/m1/s1 ☒N
  • Key:UHRBTBZOWWGKMK-DOMZBBRYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Flomoxef is an oxacephem antibiotic that was developed by Shionogi.

It has been classified either as a second-generation [1] or fourth-generation cephalosporin.[2]

It was patented in 1982 and approved for medical use in 1988 under the trade name Flumarin.[3]

References

  1. ^ Masuda Z, Kurosaki Y, Ishino K, Yamauchi K, Sano S (April 2008). "Pharmacokinetic analysis of flomoxef in children undergoing cardiopulmonary bypass and modified ultrafiltration". General Thoracic and Cardiovascular Surgery. 56 (4): 163–169. doi:10.1007/s11748-007-0208-5. PMID 18401677. S2CID 23845740.
  2. ^ Ito M, Ishigami T (1991). "The meaning of the development of flomoxef and clinical experience in Japan". Infection. 19 (Suppl 5): S253–S257. doi:10.1007/bf01645536. PMID 1783441. S2CID 25339977.
  3. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 496. ISBN 9783527607495.


Categories